Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY

Dr. Reddy's Laboratories — Q1 FY26 Earnings Presentation

14 slides from Dr. Reddy's Laboratories's earnings presentation, Jul 23, 2025

  1. Slide 1: Regulation 30 intimation cover letter

    Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com July 23, 2025 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE

  2. Slide 2: Q1FY26 Financial Results

    Q1FY26 FINANCIAL RESULTS July 23, 2025 1

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and

  4. Slide 4: Double-digit sales growth with steady profitability

    Double-digit sales growth with steady profitability Q1FY26 Performance FINANCIAL HIGHLIGHTS BUSINESS UPDATES ₹ 8,545 Cr Revenues  Collaborated with Alvotech for co-  Revenue growth ~ 11% development, manufacture & 11%YoY 0% QoQ commercialization of pembrolizumab  EBITDA Margin ~ 26.7% ₹ 2,278 Cr

  5. Slide 5: Momentum in NRT and Branded Markets offsets softness in U.S. generics

    Momentum in NRT and Branded Markets offsets softness in U.S. generics REVENUE BY SEGMENT GLOBAL GENERICS SPLIT ₹ 3,412 Cr ₹ 1,274* Cr North America Europe GLOBAL GENERICS 11%YoY 4% QoQ 142%YoY 0% QoQ 88% 15% ₹ 8,545 Cr 40% 11%YoY 0.5%QoQ PSAI 10% 17% OTHERS ₹ 1,471 Cr 2% India 11%YoY 13% QoQ ₹ 7,562

  6. Slide 6: Scaling commercial operations and channelling investments into R&D and growth-driven capex

    Scaling commercial operations and channelling investments into R&D and growth- driven capex GROSS MARGINS (% of Revenues) SG&A EXPENSES (% of Revenues) R&D EXPENSES (% of Revenues) Q1FY26 56.9% Q1FY26 30.0% Q1FY26 7.3% Q4FY25 55.6% Q4FY25 28.3% Q4FY25 8.5% Q1FY25 60.4% Q1FY25 29.6% Q1FY25 8.1% CAPEX

  7. Slide 7: North America Q1FY26 Performance

    Price Erosion and changing U.S. landscape weighs on Growth Trajectory North America Q1FY26 Performance MARKET NEW PENDING 40% PERFORMANCE LAUNCHES APPROVAL 10.8% vs. 2.3% 5 70 3 DRL Growth vs. US Generic Market Q1 ANDAs NDAs Growth* Includes 43 Para IVs & 22 FTFs *As per IQVIA MAT for May’ 25 Revenu

  8. Slide 8: India Q1FY26 Performance

    Double digit growth, outpaced market performance India Q1FY26 Performance MARKET NEW BRAND BRANDS IN 17% PERFORMANCE LAUNCHES TOP 300 IPM 11.2% vs. 8.6% 5 17 DRL Growth vs. IPM Growth* Q1 *As per IQVIA MQT Jun’ 25 As per IQVIA Jun’25 Revenues ₹ 1,471 Cr MARKET THERAPY BRANDS WITH 11%YoY 13% QoQ RANK

  9. Slide 9: Emerging Markets Q1FY26 Performance

    Emerging Sustained momentum backed by volume growth, new product Markets Q1FY26 launches & currency tailwinds Performance REVENUE SPLIT 16% ₹ 708 Cr Russia 28%YoY 8% QoQ  Growth in Constant currency : +17% YoY  Volume growth and favourable NEW CISR forex LAUNCHES Revenues 14% ₹ 195 Cr ₹ 1,404 Cr R

  10. Slide 10: Europe Q1FY26 Performance

    Revenue gains from NRT portfolio and product launches Europe Q1FY26 Performance REVENUE SPLIT 15% ₹ 669 Cr Acquired NRT Business 12% QoQ ₹ 316 Cr Germany NEW Acquired 13%YoY 11% QoQ LAUNCHES Revenues France, Italy, NRT ₹ 1,274* Cr Others 9% Business 52% 13 ₹ 173 Cr 142%YoY 0% QoQ UK Q1 UK Excluding

  11. Slide 11: PSAI Q1FY26 Performance

    Margin compression in PSAI Business primarily due to lower PSAI operating leverage Q1FY26 Performance 10% GROSS NEW Revenues MARGIN FILINGS (DMFs) ₹ 818 Cr 13% 23% 12 7%YoY 14% QoQ Q1FY26 Q1FY25 Q1 GROWTH DRIVERS  YoY: New API product launches & growth in CDMO business  QoQ: Decline due to seasona

  12. Slide 12: In Summary

    In Summary A diversified business model with broad based levers STRENGTHEN CORE BUSINESSES ACROSS MARKETS WITH A ROBUST PRODUCT PORTFOLIO INVEST IN INNOVATIVE & DIFFRENTIATED PRODUCTS (NCEs, CDMO, CONSUMER HEALTH) DRIVE OPERATIONAL EFFICIENCY & PRODUCTIVITY FOCUS ON QUALITY AND COMPLIANCE STRENGTHEN

  13. Slide 13: About key metrics and non-GAAP Financial Measures

    About key metrics and non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are a

  14. Slide 14: Good Health Can't Wait

    Good Health Can’t Wait. 13 | July 23, 2025 | Q1FY26 Results Update | As per consolidated financial statements under IFRS

Dr. Reddy's Laboratories — Q1 FY26 Earnings Presentation on 6ix